A pioneering trial of a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) has commenced at Moorfields Eye Hospital following a successful operation on a patient.
Category Archives: Age-related Macular Degeneration
To know more about Age-related Macular Degeneration, please click here.
Aflibercept in AMD patients previously treated with other anti-VEGFs
Patients with active exudative age-related macular degeneration (AMD) are being treated with various treatment regimen, which may include intravitreal ranibizumab (lucentis), bevacizumab (avastin), aflibercept (eylea), etc. Some of these patients do not show benefit from these treatments, including repeat injections in many cases.
AMD likely to be more in people with deficient vitamin D status
A multi-institutional team reports that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease. In a paper published in JAMA Ophthalmology online, the team found that women who are deficient in
READ MORE…
Amniotic membrane derived stem cell transplants show benefit in retinal diseases
A team of researchers at the CHA University in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy, which is used to simulate many retinal diseases. The treatment aimed at suppressing abnormal angiogenesis (blood vessel growth) which is recognized
READ MORE…
Belize July 2015
This trip was supported by Allergan Foundation, with instrument support from IRIDEX. Our CEO Dr Raj Agrawal made his second trip to Belize recently. This time, apart from seeing patients in Belize City, he also traveled to Orange Walk, which is an hour’s drive away from Belize City, as well as to Dangriga, which is
READ MORE…
Is Avastin better than Lucentis for AMD?
A group of researchers from China have evaluated randomized controlled clinical trials from around the world to study the efficacy and safety of Avastintm (bevacizumab) versus Lucentistm (ranibizumab) in wet (neovascular) age-related macular degeneration (AMD).
AMD may be triggered by tiny mineral deposits in retina
Scientists from the University of Maryland School of Medicine have found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD). This is the first time these mineral deposits have been implicated in the disease, which affects more than 10 million Americans.
Prof. Robin Ali on retinal cell transplantation
Prof. Robin Ali describes efforts to transplant healthy rod and cone cells into afflicted retinas. To listen, click here.
Poor Avastin responders in AMD & DME may have increased risk to obstructive sleep apnea
Poor responders to Bevacizumab (Avastin) in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) may have increased risk to obstructive sleep apnea (OSA). Read more…
Nanotechnology breakthrough will lead to a better artificial retina for visually impaired
Scientists from Hebrew University of Jerusalem researchers in collaboration with colleagues from Tel Aviv University and Newcastle University, have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Read more…